McMaster University

CloudMD Announces Results of the Annual General & Special Meeting

Retrieved on: 
Tuesday, November 9, 2021

VANCOUVER, British Columbia, Nov. 09, 2021 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the Company or CloudMD), a healthcare technology company transforming the delivery of care, has announced the results of its annual general and special meeting (AGM) held today, November 9, 2021.

Key Points: 
  • VANCOUVER, British Columbia, Nov. 09, 2021 (GLOBE NEWSWIRE) -- CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the Company or CloudMD), a healthcare technology company transforming the delivery of care, has announced the results of its annual general and special meeting (AGM) held today, November 9, 2021.
  • The Company further announces that it has appointed Duncan Hannay and Karen Adams to the Board of Directors of CloudMD.
  • It is a very exciting time for CloudMD and I am confident in our ability to continue adding long term shareholder value.
  • CloudMD is transforming the delivery of healthcare using technology and by providing a patient-centric approach, with an emphasis on continuity of care.

Fusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., as Chief Scientific Officer

Retrieved on: 
Tuesday, November 2, 2021

HAMILTON, Ontario and BOSTON, Nov. 2, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Christopher Leamon, Ph.D., as chief scientific officer. Dr. Leamon brings to Fusion more than 25 years of experience developing precision medicines and radiopharmaceuticals.

Key Points: 
  • HAMILTON, OntarioandBOSTON, Nov. 2, 2021 /PRNewswire/ --Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Christopher Leamon, Ph.D., as chief scientific officer.
  • Dr. Leamon brings to Fusion more than 25 years of experience developing precision medicines and radiopharmaceuticals.
  • Prior to Novartis, he was vice president, discovery research at Advanced Accelerator Applications, a subsidiary acquired by Novartis in 2018.
  • Eric Burak, Ph.D., Fusion's chief scientific officer since the company's inception, has been appointed chief technology officer.

COP26: WWF-Canada experts on the ground and available for interview

Retrieved on: 
Friday, October 29, 2021

Toronto, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Experts from WWF-Canada will be on the ground in Glasgow, UK, participating in and hosting two events of national importance at the upcoming UN Climate Change Conference (COP26).

Key Points: 
  • Toronto, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Experts from WWF-Canada will be on the ground in Glasgow, UK, participating in and hosting two events of national importance at the upcoming UN Climate Change Conference (COP26).
  • This Inuit Circumpolar Council panel, supported by Brandon Laforest, senior specialist, Arctic species and ecosystems at WWF-Canada, explores Inuit knowledge and perspectives on climate change, resiliency and adaptations in northern ecosystems.
  • Other panelists include:
    Vern CheeChoo Director of Lands & Resources,MushkegowukCouncil
    Dr. AlemuGonsamo Assistant Professor, McMaster University and Canada Research Chair, Remote Sensing of Terrestrial Ecosystems
    Interviews with the panelists can be arranged following the panel on Nov. 10.
  • Helpful links for background on key issues:

Makamer, Inc. Is Awarded Six-Figure Grant to Keep Thermoplastics Out of Landfills and the Environment

Retrieved on: 
Wednesday, October 27, 2021

This program will be administered and supervised by Dr. Roozbeh Mafi, Chief Scientist at Makamer and Professor Dr. Li Xi of McMaster University .

Key Points: 
  • This program will be administered and supervised by Dr. Roozbeh Mafi, Chief Scientist at Makamer and Professor Dr. Li Xi of McMaster University .
  • The Mitacs grant will fund the R&D and bring additional research through postdoctoral internships at McMasters University in the Chemical Engineering Department.
  • "This grant will help Makamer expand research and development of bio-optimized technologies and provide learning platforms for post-doc interns to advance their skills and career," said Alex Mond, President of Makamer.
  • "I would like to thank Mitacs, McMaster University and Oligomaster for validating and approving the work of Makamer in Bioplastic technologies."

Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting its FPI-1966 and FPI-2059 Targeted Alpha Therapies

Retrieved on: 
Wednesday, October 20, 2021

HAMILTON, Ontario and BOSTON, Oct. 20, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data that provide further support of its FPI-1966 and FPI-2059 targeted alpha therapies (TATs) at the 34th Annual European Association of Nuclear Medicine Congress. These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labelled precision medicine targeting NTSR1.

Key Points: 
  • These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labelled precision medicine targeting NTSR1.
  • Data from preclinical studies of FPI-1966, a TAT designed to target and deliver actinium-225 to cancer cells expressing FGFR3, were presented in an oral presentation titled, "FGFR3 Targeted Alpha Therapeutic [225Ac]-FPI-1966 induces regression in preclinical bladder xenograft model".
  • Further, the data showed therapeutic efficacy of FPI-1966 at both single and multiple doses in a preclinical bladder cancer xenograft model.
  • Data from preclinical studies of FPI-2059, a TAT designed to target and deliver actinium-225 to cancer cells expressing neurotensin receptor 1 (NTSR1), were presented in an oral presentation titled "NTSR1 Targeted Alpha Therapeutic [225Ac]-FPI-2059 induces regression in preclinical colorectal xenograft model".

Indellient Inc. Announces Appointment of New Partners

Retrieved on: 
Tuesday, October 19, 2021

TORONTO, Oct. 19, 2021 /PRNewswire/ - Indellient Inc. is pleased to announce the appointment of Sharyl Jones and Ricky Panchal as our newest partners.

Key Points: 
  • TORONTO, Oct. 19, 2021 /PRNewswire/ - Indellient Inc. is pleased to announce the appointment of Sharyl Jones and Ricky Panchal as our newest partners.
  • Sharyl Jones joined Indellient in 2017 as a Technical Project Manager within our Project Management Office.
  • Indellient empowers clients to meet and exceed their critical technology and business objectives.
  • At Indellient, we partner with our clients to drive real innovation helping them transform and grow their business.

Pelvic health therapy device wins Canada-wide competition

Retrieved on: 
Thursday, October 14, 2021

In making her winning pitch, the product's inventor, Rachel Bartholomew, CEO of Hyivy Health, spoke about her own personal health challenges.

Key Points: 
  • In making her winning pitch, the product's inventor, Rachel Bartholomew, CEO of Hyivy Health, spoke about her own personal health challenges.
  • It inspired Bartholomewto launch Hyivy Health and create a new form of pelvic rehabilitation.
  • Bartholomew said static dilators are the only option currently available for home treatment of pelvic health problems, a device which she described as ineffective, painful and not substantially updated since 1938.
  • Winning the AGE WELL National Impact Challenge means that Hyivy Health will now be able to expedite its research and trials on menopausal women and the effects of aging on their pelvic health, Bartholomew said after the competition.

ARTMS Inc. Announces Health Canada Submission for Ga-68 Production and Tri-party Collaboration to Advance Ga-68 Imaging Products

Retrieved on: 
Thursday, October 14, 2021

ARTMS Health Canada filing will help alleviate the current supply constraints and provide innovators the ability to advance new radiopharmaceutical drugs into development.

Key Points: 
  • ARTMS Health Canada filing will help alleviate the current supply constraints and provide innovators the ability to advance new radiopharmaceutical drugs into development.
  • The Ga-68 regulatory filing in Canada is the next step in ARTMS goal to prevent the significant supply issues of this important medical isotope.
  • Any interruptions to the supply chain will negatively impact patients and drug innovators, explained Charles S. Conroy, Chief Executive Officer of ARTMS.
  • We believe ARTMS solid target approach to Ga-68 production will play a key role in increasing the availability of this important isotope.

TELUS and REACH Niagara launch new Mobile Health Clinic to provide healthcare to the homeless

Retrieved on: 
Wednesday, October 6, 2021

NIAGARA, Ontario, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Today, TELUS and REACH Niagara (Regional Essential Access to Connected Health Niagara) announced a new partnership through TELUS innovative mobile Health for Good program that will bring primary care to the underserved people in the Niagara Region.

Key Points: 
  • NIAGARA, Ontario, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Today, TELUS and REACH Niagara (Regional Essential Access to Connected Health Niagara) announced a new partnership through TELUS innovative mobile Health for Good program that will bring primary care to the underserved people in the Niagara Region.
  • The REACH Niagara Mobile Health Clinic, powered by TELUS Health, is a specially-equipped clinic on wheels that provides trauma-informed, primary medical treatments, mental health services, addiction support and COVID-19 screening directly to those who need it most.
  • The REACH Mobile Health Clinic will bring much needed healthcare services to the Niagara Region.
  • This mobile, innovative care model and partnership between REACH and TELUS Health will also serve as practical Social Medicine training for McMaster University Family Medicine residents.

Amy Shumate to lead US tax practice at RSM Canada

Retrieved on: 
Wednesday, October 6, 2021

TORONTO, Oct. 6, 2021 /CNW/ - RSM Canada a leading provider of audit, tax and consulting services focused on the middle market is pleased to announce that Amy Shumate has joined the firm as a partner and will lead the U.S. tax practice .

Key Points: 
  • TORONTO, Oct. 6, 2021 /CNW/ - RSM Canada a leading provider of audit, tax and consulting services focused on the middle market is pleased to announce that Amy Shumate has joined the firm as a partner and will lead the U.S. tax practice .
  • "She brings extensive knowledge and expertise to the team, making her a valuable addition to the RSM Canada tax practice."
  • "Amy's wide-ranging tax experience provides us with even more opportunities to support our team and clients," added Maria Severino, national tax leader at RSM Canada.
  • RSM Canada Consulting LP provides consulting services and is an affiliate of RSM US LLP, a member firm of RSM International.